Clovis NSCLC Drug Rociletinib Wins FDA Priority Review
This article was originally published in Scrip
Executive Summary
After the U.S. markets closed on Sept. 29, Clovis Oncology, Inc. said the FDA had granted a priority review to the firm's new drug application (NDA) for rociletinib as a treatment for patients with mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer who have been previously treated with an EGFR-targeted therapy and have the EGFR T790M mutation.